期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CC-5013抗肿瘤机制及其临床应用的研究进展 被引量：1

下载PDF
导出
摘要 CC-5013是沙利度胺的具有免疫调节作用的衍生物,其抗肿瘤机制包括抗血管形成,抑制细胞因子信号和免疫调节效应及直接杀伤肿瘤细胞等作用。临床试验表明,其在多发性骨髓瘤、骨髓增生异常综合征、黑色素瘤及其他实体肿瘤的治疗中具有一定的价值。本文就其抗肿瘤作用机制及临床应用的研究进展作一综述。
作者 王化泉 邵宗鸿
机构地区 中国医学科学院中国协和医科大学血液学研究所血液病医院
出处 《国外医学（输血及血液学分册）》 2005年第6期481-484,共4页 Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
关键词 CC-5013 药物治疗 肿瘤 其临床应用 抗肿瘤机制 骨髓增生异常综合征 抗肿瘤作用机制 免疫调节作用 杀伤肿瘤细胞 多发性骨髓瘤
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC 5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.Microvasc Res, 2005,69(12):56-63.
  • 2Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC 5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood,2002,100(9):3063 3067.
  • 3Payvandi F, Wu I., Zhang LH, et al. CC 1503 inhibits the expression of adhesion molecules ICAM 1 and CD44 and prevents metastasis of B16 F10 mouse melanoma ceils in an animal model.Proc Am Soc Clin Oncol, 2003, (22) : 992a.
  • 4Mitsiades CS, Milsiades N. CC-5013 (Celgene). Curr Opin Inveslig Drugs, 2004,5 (6) : 635-647.
  • 5Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer,2004,4 (4) : 314-322.
  • 6Haslett PA, Hanekom WA, Muller G, et al. Thalidomide and a thalidomide analogue drug costimulate virus specific CD8+ T cells in vitro. J Infect Dis,2003,187(6):946-955.
  • 7Payvandi F, Wu L, Haley M, et al. Immunomodulatory drugs inhibit expression of cyclooxygenase 2 from TNF alpha, IL-lbeta,and I.PS-stimulated human PBMC in a partially IL 10-dependent manner. Cell Immunol, 2004,230(2) :81-88.
  • 8Marriot* JB, Clarke IA, Dredge K, et al. Thalidomide and its analogues have distinct and opposing effects on TNF alpha and TNFR2 during co-stimulation of both CD4 (+) and CD8 (+) T cells. Clin Exp Immunol, 2002,130 (1) : 75-84.
  • 9Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther, 2003,305(3):1222-1232.
  • 10Mitsiades CS, Mitsiades N, McMullan CJ, et al. Molecular profiles of sensitivity or resistance of multiple myeloma (MM)cells to conventional and novel anti-myeloma agents:Clinical implications for rationale design of strategies to overcome drugresistance in MM. Blood, 2003,102(11):659a.

同被引文献22

  • 1Nilsson L, Ed6n P, Olsson E, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastie syndromes. Blood, 2007, 110:3005-3014.
  • 2Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profi- ling of CD34 + cells in patients with the 5q- syndrome. Br J Haematol, 2007, 139:578-589.
  • 3Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 2008, 451:335- 339.
  • 4Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 defi- ciency in zebrafish leads to developmental abnormalities and defec- tive erythropoiesis through activation of p53 protein family. Blood, 2008, 112:5228-5237.
  • 5Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expres- sion levels during lenalidomide treatment in low- and Intermediate- 1-risk myelodysplastic syndromes with chomosome 5q deletion. Eur J Haematol, 2010, 85:231-235.
  • 6Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macroeytie anemia in a mouse model of hu- man 5q - syndrome. Nat Med, 2010, 16:59-66.
  • 7Pellagatti A, Marafioti T, Paterson JC, et al. Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood, 2010, 115:2721-2723.
  • 8Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identi- fication of miR-145 and miR-146a as mediators of the 5q- syn- drome phenotype. Nat Med, 2010, 16:49-58.
  • 9Lehmann S, O' Kelly J, Raynaud S, et al. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia, 2007, 21: 1931-1936.
  • 10Garderet L, Kobari L, Mazurier C, et al. Unimpaired terminal erythroid differentiation and preserved enucleation capacity in my- elodysplastic 5q(del) clones: a single cell study. Haematologica, 2010, 95:398-405.

引证文献1

国外医学（输血及血液学分册）
2005年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部